| Date Filed | Type | Description |
| 03/25/2021 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 03/17/2021 |
SC 13D/A
| Boundless Meadow Ltd reports a 0% stake in Viela Bio, Inc. |
| 03/16/2021 |
4
| Cao Yanling (10% Owner) has filed a Form 4 on Viela Bio, Inc.|
Txns:
| Disposed/sold 8,322,353 shares
@ $53, valued at
$441.1M
|
|
| 03/16/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/16/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/15/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/15/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/15/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/15/2021 |
4
| Chan Mitchell (CFO) has filed a Form 4 on Viela Bio, Inc.|
Txns:
| Disposed/sold 37,500 shares
@ $53, valued at
$2M
Disposed/sold 50,056 options to buy
@ $41.1, valued at
$2.1M
Disposed/sold 13,000 options to buy
@ $15.84, valued at
$205.9k
Disposed/sold 30,000 options to buy
@ $8.87, valued at
$266.1k
Disposed/sold 67,500 options to buy
@ $2.84, valued at
$191.7k
|
|
| 03/15/2021 |
4
| Drappa Jorn (Chief Medical Officer) has filed a Form 4 on Viela Bio, Inc.|
Txns:
| Disposed/sold 202,661 shares
@ $53, valued at
$10.7M
Disposed/sold 71,842 options to buy
@ $41.1, valued at
$3M
Disposed/sold 64,000 options to buy
@ $15.84, valued at
$1M
Disposed/sold 165,000 options to buy
@ $2.84, valued at
$468.6k
|
|
| 03/15/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/15/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/15/2021 |
4
| Nolet Chris (Director) has filed a Form 4 on Viela Bio, Inc.|
Txns:
| Disposed/sold 26,210 options to buy
@ $19, valued at
$498k
Disposed/sold 7,358 options to buy
@ $48.96, valued at
$360.2k
|
|
| 03/15/2021 |
4
| Jacques Rachelle Suzanne (Director) has filed a Form 4 on Viela Bio, Inc.|
Txns:
| Disposed/sold 14,716 options to buy
@ $48.96, valued at
$720.5k
Disposed/sold 7,358 options to buy
@ $48.96, valued at
$360.2k
|
|
| 03/15/2021 |
4
| Ragatz William (Senior VP, Head of Commercial) has filed a Form 4 on Viela Bio, Inc.|
Txns:
| Disposed/sold 16,250 shares
@ $53, valued at
$861.3k
Disposed/sold 50,548 options to buy
@ $41.1, valued at
$2.1M
Disposed/sold 48,750 options to buy
@ $5.22, valued at
$254.5k
Disposed/sold 13,000 options to buy
@ $15.84, valued at
$205.9k
|
|
| 03/15/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/15/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/15/2021 |
POSASR
| Form POSASR - Post-effective Amendment to an automatic shelf registration statement: |
| 03/15/2021 |
8-K
| Quarterly results |
| 03/15/2021 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 03/15/2021 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 03/15/2021 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 03/12/2021 |
10-K/A
| Annual Report for the period ended December 31, 2020 [amend] |
| 03/12/2021 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 03/12/2021 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 03/10/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 03/08/2021 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 03/04/2021 |
8-K
| Quarterly results |
| 03/03/2021 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 03/03/2021 |
UPLOAD
| Form UPLOAD - SEC-generated letter: |
| 03/03/2021 |
CORRESP
| Form CORRESP - Correspondence: |
| 03/03/2021 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 03/01/2021 |
10-K
| Annual Report for the period ended December 31, 2020 |
| 03/01/2021 |
8-K
| Quarterly results |
|